Related Experiment Video
Updated: Jul 6, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18.
Benjamin A Steinberg1, Alexandria J M Braganza, Gemma Eminowicz
1Department of Medicine, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital & Harvard Medical School, Boston, MA 02115, USA.
Critical Pathways in Cardiology
|March 15, 2008
Summary
Statin doses in clinical practice are often lower than those shown effective in trials. This underdosing of statins may limit their effectiveness in managing cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Clinical trials demonstrated statin efficacy at fixed doses (e.g., 40 mg simvastatin/pravastatin) for cardiovascular event reduction.
- Current clinical practice often initiates statin therapy at lower doses, with unclear titration patterns.
Purpose of the Study:
- To examine statin dosing and low-density lipoprotein cholesterol (LDL-C) levels in patients with unstable angina and non-ST elevation myocardial infarction (UA/NSTEMI).
- To assess if statin doses are titrated upward after initial treatment in clinical practice.
Main Methods:
- Analysis of the TACTICS-TIMI 18 trial data.
- Examined statin dosing at study entry and 6-month follow-up.
- Correlated statin doses with admission LDL-C levels.
Main Results:
- 33% of UA/NSTEMI patients were on statins at entry; only 18-38% received recommended doses of simvastatin or pravastatin.
- Fewer than 50% of patients achieved LDL-C < or =100 mg/dL at presentation.
- Statin doses did not increase at 6-month follow-up despite more patients being on statins.
Conclusions:
- Statin doses in clinical practice are typically lower than those used in efficacy trials.
- Underdosing of statins is prevalent in acute coronary syndrome patients.
- Suboptimal LDL-C control may result from underutilization and underdosing of statins.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:28Dosage Regimens: Designs and Approaches
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...